Avirulins may provide a valuable chemical foundation for the development of the next generation of prophylactic medications for HIV-1 in women, according to results of a study presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019, in San Francisco, California. Although much progress has been made in decreasing the risk…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Analytical treatment interruption caused neither expansion of HIV reservoirs nor immunologic abnormalities after reinitiation of antiretroviral therapy.
Suppression maintained for up to 16 weeks in HIV-infected undergoing analytic treatment interruption
Recombinant human-lactoferrin treatment in PLWHIV receiving ART was not associated with significant improvements in inflammation or immune activation.
The FDA has approved Temixys tablets for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients weighing ≥35kg.
The new “F4” formulation is 4 times more concentrated than the version currently available on the market.
The approval of Trogarzo was supported by a clinical trial (N=40) of heavily treatment-experienced adults with multidrug resistant HIV-1 infection who continued to have high levels of HIV RNA in their blood despite antiretroviral therapy.
A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.
Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.
